9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Automated Radiochemical Synthesis of [ 18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          3-[ 18F]fluoro-4-aminopyridine, [ 18F]3F4AP, is a radiofluorinated analog of the FDA-approved drug for multiple sclerosis 4-aminopyridine (4AP). This compound is currently under investigation as a PET tracer for demyelination. We recently described a novel chemical reaction to produce metafluorinated pyridines consisting of direct fluorination of a pyridine N-oxide and the utilization of this reaction for the radiochemical synthesis of [ 18F]3F4AP. In this article, we demonstrate how to produce this tracer using an automated synthesizer and an in-house made flow hydrogenation reactor. We also show the standard quality control procedures performed before releasing the radiotracer for preclinical animal imaging studies. This semi-automated procedure may serve as the basis for future production of [ 18F]3F4AP for clinical studies.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Effects of 4-aminopyridine in patients with multiple sclerosis.

          4-Aminopyridine (4-AP) was administered to two groups of patients with multiple sclerosis (MS). The first group consisted of 5 patients with labile visual symptoms, 2 of whom had arcuate scotomata. 4-AP improved visual performance of most patients in this group and reduced the size of scotomata. The second group consisted of 5 patients with the spinal form of MS who were in a stable state; in this group 4-AP had little effect clinically or on tests of visual function.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.

            4-Aminopyridine (4-AP), a potassium channel blocker, restores conduction in blocked, demyelinated animal nerve. Its administration to multiple sclerosis (MS) patients produces transient neurological improvements. Vision improves after either oral or intravenous administration, whereas motor function improvement has been reported only with the latter. To assess further its potential as a practical symptomatic treatment, we studied the efficacy of single, oral doses of 4-AP on both visual and motor signs in MS. Twenty temperature-sensitive male MS patients were given either 10 to 25 mg of 4-AP or identically appearing lactose placebo capsules. Static quantitative perimetry, critical flicker-fusion, visual acuity, visual evoked potentials, and videotaped neurological examinations were monitored. All of 15 MS patients given 4-AP mildly to markedly improved. Motor functions (power, coordination, gait) improved in 9 of 13 involved, vision in 11 of 13, and oculomotor functions in 1 of 2. Improvements developed gradually at doses as low as 10 mg, usually beginning within 60 minutes after drug administration, and reversed gradually over 4 to 7 hours. No serious adverse effects occurred. No significant changes were observed in 5 MS patients given placebo. We conclude that orally administered 4-AP produces clinically important improvements in multiple, chronic deficits in MS. Further studies are warranted to assess efficacy and safety of prolonged administration.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging.

              Recent studies have highlighted the high sensitivity of PET imaging with (68)Ga-labeled octreotide derivatives for the detection and staging of neuroendocrine tumors. A somatostatin receptor ligand that is easily radiolabeled with (18)F-fluoride could improve the availability of PET imaging of neuroendocrine tumors. We report an alkyltrifluoroborate-octreotate conjugate that is radiolabeled in a 1-step (18)F exchange reaction in high yield and with high specific activity.
                Bookmark

                Author and article information

                Journal
                J Vis Exp
                J Vis Exp
                JoVE
                Journal of Visualized Experiments : JoVE
                MyJove Corporation
                1940-087X
                2017
                29 May 2017
                29 May 2017
                : 123
                : 55537
                Affiliations
                1Department of Neurology, The University of Chicago
                2Department of Radiology, The University of Chicago
                Author notes

                Correspondence to: Pedro Brugarolas at brugarolas@ 123456uchicago.edu

                Article
                55537
                10.3791/55537
                5608160
                28605366
                86fe4d7a-8ac1-4cc7-b616-7540d5a69377
                Copyright © 2017, Journal of Visualized Experiments

                This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

                History
                Categories
                Medicine

                Uncategorized
                medicine,issue 123,fluorine-18,radiochemistry,pet tracers,multiple sclerosis,automation
                Uncategorized
                medicine, issue 123, fluorine-18, radiochemistry, pet tracers, multiple sclerosis, automation

                Comments

                Comment on this article